| Biomarker | CXCL10 | Full name | C-X-C motif chemokine ligand 10 | Molecular Type | cytokines |
| Molecular Formula | Macromolecule | Molecular Weight | / | Core Functional Dimensions | Monitoring, activity evaluation |
| Disease(or Constitution) | Thyroid Dysfunction | Disease Subtypes | Hashimoto's thyroiditis (autoimmune) | ||
| Organ | Thyroid | Test Sample / Technology Platform | Serum (ELISA, flow cytometry) | ||
| Pathobiological Mechanisms | Th1 lymphocytes induced secretion, enlarge autoimmune inflammatory response | ||||
| Clinical Availability Status | Reflect the degree of thyroid autoinflammation | ||||
| Notes and Dynamics | TPOAb drop degree are related, to evaluate treatment response | ||||
| Biomarker | TgAb | Full name | Thyroglobulin antibody | Molecular Type | antibody |
| Molecular Formula | Macromolecule | Molecular Weight | / | Core Functional Dimensions | Diagnosis and monitoring |
| Disease(or Constitution) | Thyroid Dysfunction | Disease Subtypes | Hashimoto thyroiditis (autoimmune) | ||
| Organ | Thyroid | Test Sample / Technology Platform | Serum (chemiluminescence method, ELISA) | ||
| Pathobiological Mechanisms | Attack thyroglobulin, disrupt follicular structure, and affect hormone storage | ||||
| Clinical Availability Status | Auxiliary diagnosis index (115 IU/mL) or higher, with TPOAb joint detection | ||||
| Notes and Dynamics | Antibody titer is correlated with disease activity | ||||
| Biomarker | TSH | Full name | Thyroid stimulating hormone | Molecular Type | hormone |
| Molecular Formula | Macromolecule | Molecular Weight | / | Core Functional Dimensions | Diagnosis and Prognosis |
| Disease(or Constitution) | Thyroid Dysfunction | Disease Subtypes | Subclinical hyperthyroidism | ||
| Organ | Thyroid/Pituitary | Test Sample / Technology Platform | Serum (chemiluminescence immunoassay) | ||
| Pathobiological Mechanisms | Thyroid function was compensated hyperthyroidism, and hormone levels were still positive | ||||
| Clinical Availability Status | Diagnostic core index (< 0.1-0.4 mIU/L), FT3 FT4 / normal | ||||
| Notes and Dynamics | For a long time may increase the risk of cardiovascular disease | ||||
| Biomarker | TSH | Full name | Thyroid stimulating hormone | Molecular Type | hormone |
| Molecular Formula | Macromolecule | Molecular Weight | / | Core Functional Dimensions | Diagnosis and Prognosis |
| Disease(or Constitution) | Thyroid Dysfunction | Disease Subtypes | Subclinical hypothyroidism | ||
| Organ | Thyroid/Pituitary | Test Sample / Technology Platform | Serum (chemiluminescence immunoassay) | ||
| Pathobiological Mechanisms | Thyroid function was compensated and the hormone levels were still normal | ||||
| Clinical Availability Status | Diagnostic core index (4.2-10 mIU/L), FT4 is normal | ||||
| Notes and Dynamics | Patients with persistently elevated TSH have an increased risk of developing clinical hypothyroidism | ||||
| Biomarker | BTK mutant (C481S) | Full name | Bruton's tyrosine kinase mutant (C481S) | Molecular Type | Protein (mutant) |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prediction of treatment response and drug resistance | ||
| Disease(or Constitution) | NHL | Disease Subtypes | Mantle cell lymphoma (MCL) | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Tissues, cell lines (gene sequencing, in vitro experiments) | ||
| Pathobiological Mechanisms | Mutations lead to resistance to BTK inhibitors, guiding the selection of next-generation inhibitors | ||||
| Clinical Availability Status | Clinical validation phase: validation in relapsed/refractory patients, with sensitivity of detection requiring optimization, clinical drug resistance screening. | ||||
| Notes and Dynamics | Developing ctDNA liquid biopsy to construct mutation profiles for drug resistance assessment. | ||||
| Biomarker | CTSS | Full name | Cathepsin S | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis | ||
| Disease(or Constitution) | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | NHL | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Serum (ELISA) | ||
| Pathobiological Mechanisms | Elevated serum levels are positively correlated with HDL3a and HDL3b. | ||||
| Clinical Availability Status | Validation phase of the study: 90 subjects were validated (44 NHL cases), requiring subtype-specificity and standardized detection. | ||||
| Notes and Dynamics | Expand subtype coverage to assess specificity and promote standardization of ELISA methods. | ||||
| Biomarker | PD-L1 | Full name | Programmed death-ligand 1 | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnostic and therapeutic targets | ||
| Disease(or Constitution) | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | NHL | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Blood, tissues (flow cytometry, immunohistochemistry) | ||
| Pathobiological Mechanisms | High expression of lymphocyte apoptosis-promoting mediates immune evasion | ||||
| Clinical Availability Status | Clinical validation phase: Multi-study support value, platform consistency for testing requires optimization, partial subtype applications. | ||||
| Notes and Dynamics | Developing subtype detection guidelines and exploring their combined predictive value with CD8+ T cells. | ||||
| Biomarker | has-miR-150-5p/MALAT1, has-miR335-5p/NEAT1 | Full name | has-microR-150-5p/metastasis associated lung adenocarcinoma transcript 1, has-microR335-5p/NEAT1 | Molecular Type | Nucleic acid |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis | ||
| Disease(or Constitution) | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | NHL | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Plasma (RT-qPCR, bioinformatics) | ||
| Pathobiological Mechanisms | High-level combination association with advanced stage and poor prognosis | ||||
| Clinical Availability Status | Validation phase of the study: 113 patients were validated, requiring subtype-specific validation and detection optimization. | ||||
| Notes and Dynamics | Clarify subtype applicability, optimize testing to enhance clinical accessibility. | ||||
| Biomarker | has-miR-20a-5p/SNHG16, has-miR-181a-5p/SNHG6 | Full name | has-microR-20a-5p/small nucleolar RNA host gene 6, has-microR-181a-5p/small nucleolar RNA host gene 6 | Molecular Type | Nucleic acid (ceRNA network) |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis | ||
| Disease(or Constitution) | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | NHL | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Plasma (RT-qPCR, bioinformatics) | ||
| Pathobiological Mechanisms | Association of disease invasiveness with score, independent prognostic factor | ||||
| Clinical Availability Status | Validation phase of the study: 113 patients were validated, requiring multicenter and storage stability assessment. | ||||
| Notes and Dynamics | Establishing a prognostic scoring system to explore the value of dynamic treatment monitoring. | ||||
| Biomarker | Ikaros-pSer442/445 | Full name | Ikaros-pSer442/445 | Molecular Type | Protein (phosphorylation) |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Predicting treatment response | ||
| Disease(or Constitution) | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | B-NHL | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Tissues, cell lines (phosphoproteomics, RNA-seq) | ||
| Pathobiological Mechanisms | TG-1701 attenuates its signal, correlating with early clinical response | ||||
| Clinical Availability Status | Research Validation Phase: Validation of 6 CLL patients, requiring B-NHL subtype validation and development of detection methods. | ||||
| Notes and Dynamics | Validation of subtypes applicability and development of immunohistochemical detection for phosphorylated proteins. | ||||
| Biomarker | CD82, CD55, and CD36 | Full name | Cluster of differentiation 82, 55 and 36 | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis | ||
| Disease(or Constitution) | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | DLBCL | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Blood (single-cell RNA sequencing, CyTOF) | ||
| Pathobiological Mechanisms | Significantly overexpressed without being influenced by COO and C-MYC | ||||
| Clinical Availability Status | Research validation phase: Screening and validation of 18 patients, requiring large-sample assessment and simplified testing methods. | ||||
| Notes and Dynamics | Develop standard flow cytometry panels to reduce costs and improve accessibility. | ||||
| Biomarker | IL-10/IL-6 ratio | Full name | interleukin-10/interleukin-6 ratio | Molecular Type | Protein composition |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis | ||
| Disease(or Constitution) | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | DLBCL | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Serum, cerebrospinal fluid (cellular microbead array) | ||
| Pathobiological Mechanisms | A ratio ≥2.30 predicts SCNSL risk and adverse PFS | ||||
| Clinical Availability Status | Validation phase of the study: 56 patients were validated, requiring multicenter and alternative sample testing for exploration. | ||||
| Notes and Dynamics | Validation of multicenter value and exploration of serum as a potential alternative to cerebrospinal fluid testing. | ||||
| Biomarker | RFC3 | Full name | Replication factor C subunit 3 Gene | Molecular Type | Nucleic acid (mRNA)/protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis, therapeutic targets | ||
| Disease(or Constitution) | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | DLBCL | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Organization (GEO/TCGA analysis, immunohistochemistry) | ||
| Pathobiological Mechanisms | High expression is associated with adverse features and microenvironment deterioration, with pan-cancer prognostic value | ||||
| Clinical Availability Status | Research Validation Phase: Supported by multi-omics and pan-cancer analysis, requiring prospective validation and mechanistic studies. | ||||
| Notes and Dynamics | Conduct prospective cohort validation and conduct in-depth research on downstream pathway mechanisms. | ||||
| Biomarker | SH3GL1 | Full name | SH3 domain containing GRB2 like 1 | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis, therapeutic targets | ||
| Disease(or Constitution) | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | DLBCL | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Tissues, cell lines (immunohistochemistry, CRISPR editing) | ||
| Pathobiological Mechanisms | High expression inhibits ferroptosis and adriamycin resistance, associated with poor prognosis | ||||
| Clinical Availability Status | Research validation phase: 126 patients and cell experiment validation, requiring dynamic monitoring and drug development | ||||
| Notes and Dynamics | Developing detection antibodies and exploring targeted ferroptosis combined with chemotherapy strategies. | ||||
| Biomarker | Ki-67 | Full name | Ki-67 antigen | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis | ||
| Disease(or Constitution) | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | DLBCL | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Organization (Immunohistochemistry) | ||
| Pathobiological Mechanisms | High expression is associated with short survival and is widely used in pathological reports. | ||||
| Clinical Availability Status | Clinical validation phase: multicenter validation of value, staining scoring criteria to be standardized, routine pathological reference. | ||||
| Notes and Dynamics | Promote international unified scoring standards and explore the value of joint prediction.. | ||||
| Biomarker | CHN1 | Full name | Chimerin 1 | Molecular Type | Nucleic acid (mRNA) |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis | ||
| Disease(or Constitution) | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | DLBCL | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | |||
| Pathobiological Mechanisms | High expression is associated with favorable prognosis and correlates with cell adhesion and T-cell infiltration. | ||||
| Clinical Availability Status | Research validation phase: Screening of 1,850 cases from the database, requiring clinical sample validation and therapeutic stability assessment | ||||
| Notes and Dynamics | Clarify the mechanisms associated with the tumor microenvironment and supplement experimental validation data. | ||||